Cover image for Vol. 123 Issue 7

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.649

ISI Journal Citation Reports © Ranking: 2015: 26/213 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

  1. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer

      Harinder Brar, Liat Hogen and Al Covens

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30509

      • image
      • image

      Sentinel lymph node biopsy using technetium 99 (Tc99) and blue dye with ultrastaging is considered the most cost-effective strategy with respect to 5-year progression-free survival and morbidity-free survival. Although it is included only as an exploratory strategy in this study, sentinel lymph node biopsy with indocyanine green has the potential to be the most cost-effective strategy.

  2. Review Articles

    1. You have full text access to this OnlineOpen article
      Identifying and targeting cancer stem cells in the treatment of gastric cancer

      Tanios Bekaii-Saab and Bassel El-Rayes

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30538

      • image
      • image
      • image

      Cancer stem cells may be a key driving factor in the growth and metastasis of gastric cancer. Because gastric cancer can originate from cancer stem cells, it is necessary to review current targets of signaling pathways for cancer stem cells in gastric cancer that are being studied in clinical trials.

  3. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Comparative effectiveness of screening strategies for colorectal cancer

      Afsaneh Barzi, Heinz-Josef Lenz, David I. Quinn and Sarmad Sadeghi

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30518

      • image

      Colonoscopy remains the most effective screening tool for colorectal cancer. DNA stool testing, although interesting, is costlier and is not as effective as colonoscopy; the effectiveness gap cannot be closed by improving the sensitivity and specificity of DNA stool testing for colorectal cancer.

    2. Discipline

      Medical Oncology
      Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission

      Daniel J. Weisdorf, Heather R. Millard, Mary M. Horowitz, Parvinder S. Hyare, Richard Champlin, Vincent Ho, Marco Mielcarek, Andrew Rezvani, Keith Stockerl-Goldstein, Hanna J. Khoury, Marcos De Lima, Wael Saber, Brenda Sandmaier, Mei Jie Zhang and Mary Eapen

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30536

      • image
      • image
      • image

      Allogeneic hematopoietic cell transplantation can cure some patients with acute myeloid leukemia who achieve complete remission, but the comparative outcomes after transplantation for those who fail to achieve complete remission (primary induction failure), fail in first relapse, or fail in second complete remission are not well studied. By using left-truncated, time-to-event, multivariable regression, the comparative outcomes of hematopoietic cell transplantation in these 3 states are compared with guide expectations for clinical decision making about transplantation for patients with acute myeloid leukemia not in complete remission.

    3. Disease Site

      Breast Disease
      Treatment-associated toxicities reported by patients with early-stage invasive breast cancer

      Christopher R. Friese, Jordan M. Harrison, Nancy K. Janz, Reshma Jagsi, Monica Morrow, Yun Li, Ann S. Hamilton, Kevin C. Ward, Allison W. Kurian, Steven J. Katz and Timothy P. Hofer

      Version of Record online: 24 JAN 2017 | DOI: 10.1002/cncr.30547

      • image
      • image
      • image
      • image

      The results of the current study from a diverse, population-based sample indicate that nearly one-half of women treated for early-stage breast cancer experienced at least 1 toxicity that they rated as severe/very severe during treatment, with variations observed by treatment modality. Toxicities appear to correlate with physical function and increased health care service use.

    4. Head and Neck Disease
      Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)

      Youjin Kim, Su Jin Lee, Ji Yun Lee, Se-Hoon Lee, Jong-Mu Sun, Keunchil Park, Ho Jung An, Jae Yong Cho, Eun Joo Kang, Ha-Young Lee, Jinsoo Kim, Bhumsuk Keam, Hye Ryun Kim, Kyoung Eun Lee, Moon Young Choi, Ki Hyeong Lee and Myung-Ju Ahn

      Version of Record online: 19 JAN 2017 | DOI: 10.1002/cncr.30537

      • image
      • image

      Single-agent nintedanib shows a high rate of disease control with a long duration of disease stabilization in patients with recurrent or metastatic salivary gland cancer. Nintedanib is tolerable, and toxicities are manageable. Because of the high rate and long duration of disease control, further investigation is warranted.

    5. Discipline

      Outcomes Research
      Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

      Areej El-Jawahri, Yi-Bin Chen, Ruta Brazauskas, Naya He, Stephanie J. Lee, Jennifer M. Knight, Navneet Majhail, David Buchbinder, Raquel M. Schears, Baldeep M. Wirk, William A. Wood, Ibrahim Ahmed, Mahmoud Aljurf, Jeff Szer, Sara M. Beattie, Minoo Battiwalla, Christopher Dandoy, Miguel-Angel Diaz, Anita D'Souza, Cesar O. Freytes, James Gajewski, Usama Gergis, Shahrukh K. Hashmi, Ann Jakubowski, Rammurti T. Kamble, Tamila Kindwall-Keller, Hilard M. Lazarus, Adriana K. Malone, David I. Marks, Kenneth Meehan, Bipin N. Savani, Richard F. Olsson, David Rizzieri, Amir Steinberg, Dawn Speckhart, David Szwajcer, Helene Schoemans, Sachiko Seo, Celalettin Ustun, Yoshiko Atsuta, Jignesh Dalal, Carmem Sales-Bonfim, Nandita Khera, Theresa Hahn and Wael Saber

      Version of Record online: 19 JAN 2017 | DOI: 10.1002/cncr.30546

      • image
      • image

      The impact of depression before hematopoietic cell transplantation (HCT) on clinical outcomes after HCT is unknown. Pre-transplant depression is associated with lower survival and higher risk of acute graft-versus-host disease among allogeneic HCT recipients and longer hospital length of stay after HCT.

    6. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data

      Stephen B. Williams, Jinhai Huo, Karim Chamie, Marc C. Smaldone, Christopher D. Kosarek, Justin E. Fang, Leslie M. Ynalvez, Simon P. Kim, Karen E. Hoffman, Sharon H. Giordano and Brian F. Chapin

      Version of Record online: 18 JAN 2017 | DOI: 10.1002/cncr.30506

      • image
      • image

      The treatment of localized prostate cancer using either surgery or radiotherapy is associated with an improved overall survival benefit compared with noncancer controls. There is inherent selection bias because of unmeasured confounding variables when using cancer registry data.

    7. Psychosocial Oncology
      The impact of childhood cancer: Perceptions of adult survivors

      Victoria W. Willard, James L. Klosky, Chenghong Li, Deo Kumar Srivastava, Tara M. Brinkman, Leslie L. Robison, Melissa M. Hudson and Sean Phipps

      Version of Record online: 18 JAN 2017 | DOI: 10.1002/cncr.30514

      • image
      • image

      Perceptions of the impact of childhood cancer on functional outcomes are assessed by adult survivors enrolled on the St. Jude Lifetime Cohort Study. Generally, survivors perceive minimal impact of their cancer experience on their current functioning, although there is variation with regard to demographic variables and diagnosis of a brain tumor.

    8. Quality of Life
      You have full text access to this OnlineOpen article
      What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability

      Claire F. Snyder, Katherine C. Smith, Elissa T. Bantug, Elliott E. Tolbert, Amanda L. Blackford, Michael D. Brundage and the PRO Data Presentation Stakeholder Advisory Board

      Version of Record online: 13 JAN 2017 | DOI: 10.1002/cncr.30530

      • image
      • image
      • image
      • image

      Patient-reported outcomes (PROs) (eg, symptoms, well being) can be used for patient management and monitoring. This study informs best practices for displaying PRO results so that patients and clinicians can understand what the scores mean.

    9. Outcomes Research
      Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma

      Onur C. Kutlu, Jennifer A. Chan, Thomas A. Aloia, Yun S. Chun, Ahmed O. Kaseb, Guillaume Passot, Suguru Yamashita, Jean-Nicolas Vauthey and Claudius Conrad

      Version of Record online: 13 JAN 2017 | DOI: 10.1002/cncr.30531

      • image

      While a significant number of HCC greater than 3cm in the US are treated with RFA, RFA is associated with worse outcomes as first-line therapy when applied to tumors >3cm. Increasing the size indication by 5mm only to HCC of 35mm leads to significantly worse survival, however, RFA is an appropriate alternative for HCC <3cm with comparable outcomes to resection and ablation.

    10. Disease Site

      Breast Disease
      A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes

      Saundra S. Buys, John F. Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L. Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster and Mary B. Daly

      Version of Record online: 13 JAN 2017 | DOI: 10.1002/cncr.30498

      • image
      • image
      • image

      Testing with a 25-gene hereditary cancer panel more than doubled the number of women with a personal diagnosis of breast cancer identified as carrying a pathogenic variant relative to BRCA1/BRCA2 testing alone. In this cohort, there was no decrease in the prevalence of mutations among women diagnosed between ages 45 and 59 years compared with women ages 40 to 44 years.

    11. Discipline

      Disparities Research
      Racial disparities in treatment use for multiple myeloma

      Mark A. Fiala and Tanya M. Wildes

      Version of Record online: 13 JAN 2017 | DOI: 10.1002/cncr.30526

      In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors must be explored to fully explain the disparity.

    12. Quality of Life
      The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer

      Tina Hsu, Caroline H. Speers, Hagen F. Kennecke and Winson Y. Cheung

      Version of Record online: 12 JAN 2017 | DOI: 10.1002/cncr.30511

      • image

      Patients who experience more pronounced fatigue or lack emotional support have a higher likelihood of worse survival. Abbreviated patient-reported outcomes can inform and assist clinicians to identify patients with a worse prognosis who may require more vigilant follow-up.

    13. Disease Site

      Head and Neck Disease
      Education and support needs in patients with head and neck cancer: A multi-institutional survey

      Joe Jabbour, Chris Milross, Puma Sundaresan, Ardalan Ebrahimi, Heather L. Shepherd, Haryana M. Dhillon, Gary Morgan, Bruce Ashford, Muzib Abdul-Razak, Eva Wong, Michael Veness, Carsten E. Palme, Cate Froggatt, Ruben Cohen, Rafael Ekmejian, Jessica Tay, David Roshan and Jonathan R. Clark

      Version of Record online: 12 JAN 2017 | DOI: 10.1002/cncr.30535

      Patients with head and neck cancer have complex educational and support needs because of tumor and patient diversity. In the current study, patients highlight unmet informational needs regarding survivorship topics.

    14. Gastrointestinal Disease
      The novel fusion transcript NR5A2-KLHL29FT is generated by an insertion at the KLHL29 locus

      Zhenguo Sun, Xiquan Ke, Steven L. Salzberg, Daehwan Kim, Valentin Antonescu, Yulan Cheng, Binbin Huang, Jee Hoon Song, John M. Abraham, Sariat Ibrahim, Hui Tian and Stephen J. Meltzer

      Version of Record online: 12 JAN 2017 | DOI: 10.1002/cncr.30510

      • image
      • image
      • image

      A novel fusion transcript identified by RNA sequencing, nuclear receptor subfamily 5, group A, member 2 (NR5A2)-Kelch-like family member 29 fusion transcript (KLHL29FT), was generated from a polymorphism insertion at the KLHL29 locus instead of a chromosome rearrangement. The expression of NR5A2-KLHL29FT appears to be lower in colon cancers than in matched normal tissues, suggesting potential participation of NR5A2-KLHL29FT in the origin or progression of colon cancer.

    15. Discipline

      Disparities Research
      You have free access to this content
      Cancer preventive services, socioeconomic status, and the Affordable Care Act

      Gregory S. Cooper, Tzuyung Doug Kou, Avi Dor, Siran M. Koroukian and Mark D. Schluchter

      Version of Record online: 9 JAN 2017 | DOI: 10.1002/cncr.30476

      Although it has been assumed that the elimination of out-of-pocket expenses will reduce socioeconomic disparities in cancer screening, there is little empirical evidence to support this contention. Using Medicare data, this study shows that with the Affordable Care Act, disparities have decreased for screening mammography but not colonoscopy.

    16. Clinical Trials
      You have full text access to this OnlineOpen article
      Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer

      Joanne E. Mortimer, Sarah Waliany, Christina M. Dieli-Conwright, Sunita K. Patel, Arti Hurria, Joseph Chao, Brian Tiep and Carolyn E. Behrendt

      Version of Record online: 6 JAN 2017 | DOI: 10.1002/cncr.30426

      To identify objective measures of cancer-related fatigue, herein the authors evaluate physical, neurocognitive, and serologic markers for correlation with the Brief Fatigue Inventory before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer. Although several markers correlate with self-reported fatigue at one assessment, only the cytokine interleukin 12 appears to correlate with fatigue both before and after chemotherapy.

    17. Disease Site

      Genitourinary Disease
      Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer

      Brandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, Srikala S. Sridhar, Edith P. Mitchell, Curtis A. Pettaway, Michael A. Carducci, Paul L. Nguyen and Christopher J. Sweeney

      Version of Record online: 5 JAN 2017 | DOI: 10.1002/cncr.30503

      • image

      Among patients diagnosed with distant, de novo, metastatic prostate cancer, Asian men have a superior outcome compared with men of other races. Furthermore, black men and non-Hispanic white men have comparable outcomes when they receive treatment with androgen-deprivation therapy or chemohormonal therapy.

    18. Discipline

      Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers

      Shu-Lin Chuang, William Wang-Yu Su, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Cheng-Ping Wang, Jean Ching-Yuan Fann, Sherry Yueh-Hsia Chiu, Yi-Chia Lee, Han-Mo Chiu, Dun-Cheng Chang, Yann-Yuh Jou, Chien-Yuan Wu, Hsiu-Hsi Chen, Mu-Kuan Chen and Shu-Ti Chiou

      Version of Record online: 5 JAN 2017 | DOI: 10.1002/cncr.30517

      • image
      • image
      • image
      • image

      Significant reductions in stage III and IV oral cancers and in deaths from oral cancer resulting from a population-based, organized service that screens 2 million Taiwanese cigarette smokers and/or betel quid chewers not only demonstrate the reproducibility of screening by oral visual inspection in a randomized, controlled trial but also highlight the applicability of such screening to the prevention of oral cancer in high-risk individuals from areas with a high incidence of oral cancer.